Effects of prescribed antithrombotics and other cardiovascular pharmacotherapies on all-cause mortality in patients with diabetes and atrial fibrillation - A cohort study from Sweden using propensity score analyses

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Wändell, Per ^a   Carlsson, Axel C ^a,b   Sundquist, Jan ^c,d   Johansson, Sven Erik ^c   Bottai, Matteo ^a   Sundquist, Kristina ^c,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antithrombotic drugs; Follow up; Mortality; Pharmacotherapy; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; EDUCATION; FEMALE; FOLLOW UP; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HUMAN; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MIDDLE AGED; MORBIDITY; MORTALITY; OUTCOME VARIABLE; PRESCRIPTION; PRIMARY HEALTH CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; SEX RATIO; SWEDEN; VERY ELDERLY;

EID: 84892169809     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-2     Document Type: Article

References (44)

1. Estimating disease prevalence using a population-based administrative healthcare database. Wirehn AB, Karlsson HM, Carstensen JM, Scand J Public Health 2007 35 4 424 431 10.1080/14034940701195230 17786807 (Pubitemid 47386793)
2. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Huxley RR, Filion KB, Konety S, Alonso A, Am J Cardiol 2011 108 1 56 62 10.1016/j.amjcard.2011.03.004 21529739
3. Treatment of atrial fibrillation. Bajpai A, Savelieva I, Camm AJ, Br Med Bull 2008 88 1 75 94 10.1093/bmb/ldn046 19059992
4. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Kannel WB, Wolf PA, Benjamin EJ, Levy D, Am J Cardiol 1998 82 8A 2N 9N 9809895 (Pubitemid 28507114)
5. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Humphries KH, Kerr CR, Connolly SJ, Klein G, Boone JA, Green M, Sheldon R, Talajic M, Dorian P, Newman D, Circulation 2001 103 19 2365 2370 10.1161/01.CIR.103.19.2365 11352885 (Pubitemid 32448801)
6. Gender in atrial fibrillation: ten years later. Michelena HI, Powell BD, Brady PA, Friedman PA, Ezekowitz MD, Gend Med 2010 7 3 206 217 10.1016/j.genm.2010.06.001 20638626
7. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Hart RG, Pearce LA, Aguilar MI, Ann Intern Med 2007 146 12 857 867 10.7326/0003-4819-146-12-200706190-00007 17577005 (Pubitemid 351650486)
8. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Lip GY, Lane DA, Am J Med 2010 123 9 785 789 10.1016/j.amjmed.2010.01.031 20655037
9. Atrial fibrillation and mortality: the impact of antithrombotic therapy. Lane DA, Lip GY, Eur Heart J 2010 31 17 2075 2076 10.1093/eurheartj/ehp486 20685675
10. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Aguilar MI, Hart R, Pearce LA, Cochrane Database Syst Rev 2007 3 CD006186
11. Effect of a multifactorial intervention on mortality in type 2 diabetes. Gaede P, Lund-Andersen H, Parving HH, Pedersen O, N Engl J Med 2008 358 6 580 591 10.1056/NEJMoa0706245 18256393 (Pubitemid 351214285)
12. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C, Lancet 2008 371 9607 117 125 10.1016/S0140-6736(08)60104-X 18191683
13. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR, Diabetologia 2006 49 8 1761 1769 10.1007/s00125-006-0297-1 16736131 (Pubitemid 44025030)
14. Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors' adherence to warfarin therapy recommendations: a Swedish study of prescribed drugs in primary care in 2002 and 2007. Carlsson AC, Wandell P, Sundquist K, Johansson SE, Sundquist J, Eur J Clin Pharmacol 2013 69 2 245 253 10.1007/s00228-012-1322-6 22684091
15. Effect of cardiovascular drug classes on all-cause mortality among atrial fibrillation patients treated in primary care in Sweden: a cohort study. Wandell P, Carlsson AC, Sundquist K, Johansson SE, Sundquist J, Eur J Clin Pharmacol 2013 69 2 279 287 10.1007/s00228-012-1395-2 22990327
16. Coronary heart disease risks in first- and second-generation immigrants in Sweden: a follow-up study. Sundquist K, Li X, J Intern Med 2006 259 4 418 427 10.1111/j.1365-2796.2006.01630.x 16594910 (Pubitemid 43384233)
17. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. Almgren T, Wilhelmsen L, Samuelsson O, Himmelmann A, Rosengren A, Andersson OK, J Hypertens 2007 25 6 1311 1317 10.1097/HJH.0b013e328122dd58 17563546 (Pubitemid 46918812)
18. Total mortality among levothyroxine-treated women with atrial fibrillation in Swedish primary health care. Wandell PE, Carlsson AC, Sundquist K, Johansson SE, Sundquist J, Int J Cardiol 2011 152 1 147 148 10.1016/j.ijcard.2011.07.066 21851994
19. Laplace regression with censored data. Bottai M, Zhang J, Biom J 2010 52 4 487 503 10.1002/bimj.200900310 20680972
20. Evaluating percentiles of survival. Orsini N, Wolk A, Bottai M, Epidemiology 2012 23 5 770 771 10.1097/EDE.0b013e3182625eff 22872120
21. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). Friberg L, Hammar N, Ringh M, Pettersson H, Rosenqvist M, Eur Heart J 2006 27 16 1954 1964 10.1093/eurheartj/ehl146 16847008 (Pubitemid 44297370)
22. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, et al. Europace 2006 8 9 651 745 16987906 (Pubitemid 44472247)
23. Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes. Dahabreh IJ, Sheldrick RC, Paulus JK, Chung M, Varvarigou V, Jafri H, Rassen JA, Trikalinos TA, Kitsios GD, Eur Heart J 2012 33 15 1893 1901 10.1093/eurheartj/ehs114 22711757
24. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, Belmin J, Cochrane Database Syst Rev 2012 5 CD005049
25. Digitalis in heart failure! Still applicable? Hoppe UC, Erdmann E, Z Kardiol 2005 94 5 307 311 10.1007/s00392-005-0219-0 15868358 (Pubitemid 40684966)
26. Effect of diabetes on alteration of metabolism in cardiac myocytes: therapeutic implications. Kota SK, Jammula S, Panda S, Modi KD, Diabetes Technol Ther 2011 13 11 1155 1160 10.1089/dia.2011.0120 21751873
27. New insights into diastolic heart failure: role of diabetes mellitus. Piccini JP, Klein L, Gheorghiade M, Bonow RO, Am J Med 2004 116 Suppl 5A 64S 75S 15019864 (Pubitemid 38333042)
28. Influence of gender on long-term prognosis of patients with chronic heart failure seen in heart failure clinics. Jimenez-Navarro MF, Ramirez-Marrero MA, Anguita-Sanchez M, Castillo JC, Clin Cardiol 2010 33 3 13 18 10.1002/clc.20476
29. Atrial fibrillation in congestive heart failure. Seiler J, Stevenson WG, Cardiol Rev 2010 18 1 38 50 10.1097/CRD.0b013e3181c21cff 20010337
30. Digoxin for the treatment of chronic and acute heart failure syndromes. Gheorghiade M, Harinstein ME, Filippatos GS, Acute Card Care 2009 11 2 83 87 10.1080/17482940902883246 19384675
31. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Schrier RW, Masoumi A, Elhassan E, Clin J Am Soc Nephrol 2010 5 6 1132 1140 10.2215/CJN.01410210 20448074
32. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ, Circulation 1999 100 12 1311 1315 10.1161/01.CIR.100.12.1311 10491376 (Pubitemid 29440124)
33. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E, J Am Coll Cardiol 2003 42 4 705 708 10.1016/S0735-1097(03)00765-4 12932605 (Pubitemid 37000189)
34. Effect of beta-blockers on the risk of atrial fibrillation in patients with acute myocardial infarction. Pesaro AE, de Matos SA, Serrano CV, Giraldez RR, Ladeira RT, Nicolau JC, Clinics (Sao Paulo) 2010 65 3 265 270 10.1590/S1807-59322010000300005 20360916
35. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. CIBIS-II Investigators and Committees, Lancet 1999 353 9146 9 13 10023943
36. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). MERIT-HF Study Group, Lancet 1999 353 9169 2001 2007 10376614
37. Lipid-altering therapy and atrial fibrillation. Bachmann JM, Majmudar M, Tompkins C, Blumenthal RS, Marine JE, Cardiol Rev 2008 16 4 197 204 10.1097/CRD.0b013e318177271d 18562810
38. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Friberg J, Scharling H, Gadsboll N, Truelsen T, Jensen GB, Am J Cardiol 2004 94 7 889 894 10.1016/j.amjcard.2004.06.023 15464671 (Pubitemid 39359174)
39. Five-year mortality in men and women with atrial fibrillation. Wandell PE, Scand J Prim Health Care 2001 19 2 112 116 10.1080/028134301750235358 11482411 (Pubitemid 32601774)
40. Mortality in diabetes compared with previous cardiovascular disease: a gender-specific meta-analysis. Lee C, Joseph L, Colosimo A, Dasgupta K, Diabetes Metab 2012 38 5 420 427 10.1016/j.diabet.2012.04.002 22682738
41. The role of 'confounding by indication' in assessing the effect of quality of care on disease outcomes in general practice: results of a case-control study. de Koning JS, Klazinga NS, Koudstaal PJ, Prins A, Borsboom GJ, Mackenbach JP, BMC Health Serv Res 2005 5 1 10 10.1186/1472-6963-5-10 15676067 (Pubitemid 40300816)
42. Confounding and indication for treatment in evaluation of drug treatment for hypertension. Grobbee DE, Hoes AW, BMJ 1997 315 7116 1151 1154 10.1136/bmj.315.7116.1151 9374894 (Pubitemid 27470317)
43. Country of birth, socioeconomic factors, and risk factor control in patients with type 2 diabetes: a Swedish study from 25 primary health-care centres. Sundquist K, Chaikiat A, Leon VR, Johansson SE, Sundquist J, Diabetes Metab Res Rev 2011 27 3 244 254 10.1002/dmrr.1161 21309045
44. Stratification for the propensity score compared with linear regression techniques to assess the effect of treatment or exposure. Senn S, Graf E, Caputo A, Stat Med 2007 26 30 5529 5544 10.1002/sim.3133 18058851 (Pubitemid 351193579)